(Q71181717)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8678094%20AND%20SRC:MED&resulttype=core&format=json

16 October 2019

title

Comparative activity of eight antimicrobial agents against clinical bacterial isolates from the United States, measured by two methods (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8678094%20AND%20SRC:MED&resulttype=core&format=json

16 October 2019

main subject

United States of America

1 reference

1 reference

C Thornsberry

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8678094%20AND%20SRC:MED&resulttype=core&format=json

16 October 2019

Y C Yee

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8678094%20AND%20SRC:MED&resulttype=core&format=json

16 October 2019

publication date

1 June 1996

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8678094%20AND%20SRC:MED&resulttype=core&format=json

American Journal of Medicine

16 October 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8678094%20AND%20SRC:MED&resulttype=core&format=json

16 October 2019

volume

100

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8678094%20AND%20SRC:MED&resulttype=core&format=json

16 October 2019

issue

6A

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8678094%20AND%20SRC:MED&resulttype=core&format=json

16 October 2019

page(s)

26S-38S

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8678094%20AND%20SRC:MED&resulttype=core&format=json

Susceptibility of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over a 5-year period

16 October 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900105-2

Outer membrane permeability and beta-lactamase stability of dipolar ionic cephalosporins containing methoxyimino substituents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900105-2

In vitro activities of cefepime alone and with amikacin against aminoglycoside-resistant gram-negative bacteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900105-2

Diffusion of beta-lactam antibiotics through the porin channels of Escherichia coli K-12

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900105-2

Novel method for measurement of outer membrane permeability to new beta-lactams in intact Enterobacter cloacae cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900105-2

Factors involved in the enhanced efficacy against gram-negative bacteria of fourth generation cephalosporins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900105-2

Evaluation of the in vitro activity of BMY-28142, a new broad-spectrum cephalosporin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900105-2

Comparison of cefepime, cefpirome, and cefaclidine binding affinities for penicillin-binding proteins in Escherichia coli K-12 and Pseudomonas aeruginosa SC8329

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900105-2

Activities of beta-lactam antibiotics against Escherichia coli strains producing extended-spectrum beta-lactamases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900105-2

Antimicrobial activity of cefepime tested against Bush group I beta-lactamase-producing strains resistant to ceftazidime. A multilaboratory national and international clinical isolate study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900105-2

Characterization of beta-lactamases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900105-2

Classification of beta-lactamases: groups 1, 2a, 2b, and 2b'.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900105-2

Classification of beta-lactamases: groups 2c, 2d, 2e, 3, and 4.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900105-2

In-vitro activity of cefepime and other antimicrobials: survey of European isolates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900105-2

Multicenter comparison of in vitro activities of FK-037, cefepime, ceftriaxone, ceftazidime, and cefuroxime

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900105-2

Antimicrobial activity of new antibiotics against bacterial isolates from a community hospital.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900105-2

Antibacterial activity of cefepime in vitro.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900105-2

Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900105-2

Major trends in the microbial etiology of nosocomial infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900105-2

A comparative study of the in-vitro activity of cefepime and other antimicrobial agents against penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900105-2

10.1016/S0002-9343(96)00105-2

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8678094%20AND%20SRC:MED&resulttype=core&format=json

16 October 2019

1 reference